These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39362194)

  • 1. Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis.
    Nichani PAH; Popovic MM; Mihalache A; Pathak A; Muni RH; Wong DTW; Kertes PJ
    Ophthalmologica; 2024; 247(5-6):355-372. PubMed ID: 39362194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
    Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
    Graefes Arch Clin Exp Ophthalmol; 2024 Nov; 262(11):3437-3451. PubMed ID: 38847896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.
    Tadayoni R; Paris LP; Danzig CJ; Abreu F; Khanani AM; Brittain C; Lai TYY; Haskova Z; Sakamoto T; Kotecha A; Schlottmann PG; Liu Y; Seres A; Retiere AC; Willis JR; Yoon YH;
    Ophthalmology; 2024 Aug; 131(8):950-960. PubMed ID: 38280653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
    Khanani AM; Kotecha A; Chang A; Chen SJ; Chen Y; Guymer R; Heier JS; Holz FG; Iida T; Ives JA; Lim JI; Lin H; Michels S; Quezada Ruiz C; Schmidt-Erfurth U; Silverman D; Singh R; Swaminathan B; Willis JR; Tadayoni R;
    Ophthalmology; 2024 Aug; 131(8):914-926. PubMed ID: 38382813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema.
    Maguire M; Laidlaw D; Davies N; Hammond C
    Graefes Arch Clin Exp Ophthalmol; 2024 Nov; 262(11):3501-3508. PubMed ID: 38771336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on corneal endothelium of intravitreal injection of anti-VEGF drugs.
    Malvasi M; Calandri A; Pacella E; Vingolo EM
    Cutan Ocul Toxicol; 2024 Dec; 43(4):369-382. PubMed ID: 39560148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Short-Term Efficacy and Safety of Faricimab in Refractory Neovascular Age-Related Macular Degeneration: The Real-World Experience in Taiwan.
    Chi SC; Weng CC; Chen SJ; Lin TC; Chou YB; Hwang DK
    Ophthalmologica; 2024; 247(5-6):312-321. PubMed ID: 39197428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema.
    Diack C; Avery RL; Cheung CMG; Csaky KG; Gibiansky L; Jaminion F; Gibiansky E; Sickert D; Stoilov I; Cosson V; Bogman K
    Transl Vis Sci Technol; 2024 Nov; 13(11):13. PubMed ID: 39535745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema.
    Borchert GA; Kiire CA; Stone NM; Akil H; Gkika T; Fischer MD; Xue K; Cehajic-Kapetanovic J; MacLaren RE; Charbel Issa P; Downes SM; De Silva SR
    Eye (Lond); 2024 Dec; 38(18):3569-3577. PubMed ID: 39394370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study.
    Wolf S; Stanga PE; Veselovsky M; Veith M; Papp A; Mange S; Kanta Mondal L; Romanczak D; Janco L; Chauhan R; Romanowska-Dixon B; Eremina A; Zavgorodnya N; Dusova J; Sagong M; Kim S; Ahn K; Kim S; Bae Y; Lee S; Kang H; Brown DM
    Ophthalmol Retina; 2024 Dec; 8(12):1163-1173. PubMed ID: 38942386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population.
    Fukuda Y; Notomi S; Shiose S; Maehara Y; Kiyohara K; Fujiwara K; Hashimoto S; Kano K; Ishikawa K; Hisatomi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2024 Dec; 262(12):3971-3978. PubMed ID: 39073562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.
    Jhaveri CD; Liu D; Maguire MG; Glassman AR; Grigorian RA; Jampol LM; Kingsley RM; MacCumber MW; Martin DF; Maturi RK; Velez G; Sun JK;
    Ophthalmology; 2024 Aug; 131(8):967-974. PubMed ID: 38336282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
    Dervenis P; Dervenis N; Smith JM; Steel DH
    Cochrane Database Syst Rev; 2023 May; 5(5):CD008214. PubMed ID: 37260074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aflibercept in a real-world setting: the AURIGA study : 24-month results of the German cohort of treatment-naïve patients with macular edema following retinal vein occlusion receiving intravitreal aflibercept].
    Wachtlin J; Kaymak H; Hoerauf H; Allmeier H; Machewitz T; Scholz P; Schürks M; Feltgen N
    Ophthalmologie; 2024 Aug; 121(8):650-657. PubMed ID: 38976039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world study.
    Singh DV; Agarwal A; Goyal A; Shroff D; Singh J; Kumar P; Reddy RR; Venkatesh R; Narnaware S; Joshi S; Singh DV; Narula R; Joshi A; Agarwal A; Goyal A; Gupta C; Shroff D; Anantharaman G; Singh J; Kumar P; Bawankule P; Reddy RR; Jain R; Venkatesh R; Tiwari R; Sugumar S; Gupta SR; Narnaware S; Joshi S; Choudhary SP;
    Indian J Ophthalmol; 2024 Dec; 72(12):1786-1794. PubMed ID: 39620667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial.
    Nielsen JS; Chang A; Holekamp NM; Cavichini-Cordeiro M; Lin SL; Heinrich D; Maass KF; Menezes A; Singh N; Pieramici DJ
    Ophthalmol Retina; 2024 Dec; 8(12):1127-1139. PubMed ID: 38914294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials.
    Sun H; Li L; Bu F; Xin X; Yan J; Huang T
    Eye (Lond); 2024 Dec; 38(18):3473-3480. PubMed ID: 39261653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology.
    Nakao S; Kusuhara S; Murakami T
    Graefes Arch Clin Exp Ophthalmol; 2024 Dec; 262(12):3749-3759. PubMed ID: 38995350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of choroidal structure changes after intravitreal anti-VEGF therapy for retinal vein occlusion.
    Dursun E; Derhem B; Çobanoğlu S; Oğurel T
    Graefes Arch Clin Exp Ophthalmol; 2024 Dec; 262(12):3837-3845. PubMed ID: 39037469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.